Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual β-cell function

Diabetes Care

Volumn 34, Issue 7, 2011, Pages 1463-1468

  Kielgast, Urd ^a,b   Krarup, Thure ^c   Holst, Jens Juul ^b   Madsbad, Sten ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; ANTIDIABETIC AGENT; C PEPTIDE; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1;

ABDOMINAL DISTENSION; ADULT; ARTICLE; BICYCLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL ARTICLE; DIABETIC PATIENT; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HALITOSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; MALE; PANCREAS ISLET CELL FUNCTION; PATIENT SATISFACTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; ADOLESCENT; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EXERCISE TEST; MIDDLE AGED; PANCREAS ISLET BETA CELL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; EXERCISE TEST; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; WEIGHT LOSS;

EID: 80054690193     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0096     Document Type: Article

References (20)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439 (Pubitemid 350041474)
2. Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008;11:491-499
3. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009;23:463-477
4. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-830 (Pubitemid 34233752)
5. Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Evaluation of β-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 2000;23:807-812 (Pubitemid 30414198)
6. Kielgast U, Holst JJ, Madsbad S. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev 2009;5: 266-275
7. Behme MT, Dupré J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord 2003;3:3
8. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996;19:580-586
9. Dupre J, Behme MT, Hramiak IM, et al. Glucagon-like peptide I reduces post-prandial glycemic excursions in IDDM. Diabetes 1995;44:626-630
10. Dupré J, Behme MT, Hramiak IM, McDonald TJ. Subcutaneous glucagonlike peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM. Diabetes Care 1997;20:381-384 (Pubitemid 27098228)
11. Dupré J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004;89:3469-3473 (Pubitemid 38951922)
12. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326: 1316-1322
13. Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on β-cell function in long-standing type 1 diabetes. Diabetes Care 2009;32:2251-2257
14. Raman VS, Mason KJ, Rodriguez LM, et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010;33:1294-1296
15. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-520 (Pubitemid 28084232)
16. Gutzwiller JP, Göke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999; 44:81-86 (Pubitemid 29143284)
17. Hilsted J, Jensen SB. A simple test for autonomic neuropathy in juvenile diabetics. Acta Med Scand 1979;205:385-387 (Pubitemid 9181306)
18. Medtronic. iPro, Manual Guide. København, Denmark, Medtronic, 2011
19. Knudsen LB, Jelsing J, Vrang N, Tang-Christensen M, Raun K. Liraglutide: short lived effect on gastric emptying-longlasting effects on body-weight (Abstract). Diabetes 2010;59:A161
20. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87:1239-1246 (Pubitemid 36121094)